Trial Profile
A first-in-human single-patient, investigator-initiated clinical trial of RGX-181 for the treatment of ceroid lipofuscinosis type 2 (CLN2) disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs RGX-181 (Primary)
- Indications Neuronal ceroid lipofuscinosis
- Focus Adverse reactions; First in man
- 30 Aug 2023 Initial interim data from a first-in-human single-patient, investigator-initiated trial of RGX-181 presented in the REGENXBIO Media Release
- 30 Aug 2023 According to a REGENXBIO media release, initial interim data from a first-in-human single-patient, investigator-initiated trial of RGX-181 presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Jerusalem.
- 23 Aug 2023 Status changed from planning to recruiting, according to a REGENXBIO media release.